APLT - NASDAQ
Applied Therapeutics, Inc.
$0.91
+0.0000%Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
At a Glance
Live SnapshotApplied Therapeutics, Inc. Management Team
Mr. Corwin Dale Hooks
Chief Commercial Officer
Compensation
$636,739
Dr. Riccardo Perfetti M.D., Ph.D.
Chief Medical Officer
Compensation
$860,761
Mr. Constantine Chinoporos
Chief Operating Officer & Chief Business Officer
Dr. Todd F. Baumgartner M.D., M.P.H.
Chief Regulatory Officer
Mr. John H. Johnson
Executive Chairman
Compensation
$378,840
Ms. Reena Thomas Colacot
Head of Quality
Ms. Catherine Thorpe
Interim Chief Accounting Officer
Mr. Les D. Funtleyder
Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director
Compensation
$768,846
Applied Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $237K and sold $7K worth of APLT shares, resulting in $230K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
600.0K
237.00K
4.9K
7.32K
+230K
+$230K
Top Buyers
Lerner Teena
Director
$79K
Kanter Stacy J.
Director
$79K
Skyler Jay S
Director
$79K
Top Sellers
Bailey Evan Prescott
Officer: Chief Medical Officer
$7K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $230K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
APLT - Filing history and reports
No SEC filings available for APLT
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.